| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 96361 |
Intravenous infusion, hydration; each additional hour |
10,031 |
7,676 |
$3.31M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
16,862 |
14,545 |
$2.67M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
17,548 |
14,732 |
$2.52M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
17,452 |
15,142 |
$2.45M |
| G0378 |
Hospital observation service, per hour |
3,012 |
2,468 |
$682K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
3,028 |
2,730 |
$599K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,300 |
2,934 |
$596K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,833 |
1,645 |
$516K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,067 |
2,711 |
$419K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
3,939 |
2,982 |
$415K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
6,132 |
4,637 |
$409K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
2,905 |
2,468 |
$370K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,536 |
2,288 |
$330K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
1,652 |
872 |
$295K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
5,096 |
4,784 |
$282K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,060 |
656 |
$228K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,436 |
1,285 |
$199K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
889 |
792 |
$170K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,868 |
1,120 |
$168K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,599 |
3,948 |
$165K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
681 |
633 |
$158K |
| 80053 |
Comprehensive metabolic panel |
31,241 |
23,954 |
$152K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,416 |
1,220 |
$132K |
| 59025 |
Fetal non-stress test |
739 |
521 |
$125K |
| 93971 |
|
870 |
780 |
$96K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
913 |
849 |
$84K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
500 |
261 |
$75K |
| 93017 |
|
291 |
266 |
$63K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
660 |
590 |
$61K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,543 |
2,117 |
$52K |
| 71046 |
Radiologic examination, chest; 2 views |
10,114 |
8,668 |
$42K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
11,318 |
9,431 |
$40K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,134 |
1,037 |
$38K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
512 |
471 |
$33K |
| 83880 |
|
2,284 |
1,930 |
$27K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
5,527 |
4,182 |
$25K |
| 80329 |
|
1,646 |
1,117 |
$23K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,500 |
1,307 |
$21K |
| 70496 |
|
72 |
65 |
$21K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
135 |
130 |
$20K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
994 |
793 |
$18K |
| 93246 |
|
262 |
253 |
$18K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
746 |
594 |
$17K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
28,413 |
21,180 |
$17K |
| 84484 |
|
11,315 |
8,234 |
$14K |
| 93000 |
|
6,635 |
5,388 |
$13K |
| 87040 |
|
1,298 |
849 |
$13K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
963 |
881 |
$11K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
13 |
12 |
$11K |
| 85380 |
|
1,534 |
1,387 |
$10K |
| 74018 |
|
623 |
537 |
$10K |
| 93325 |
|
247 |
230 |
$9K |
| 90715 |
|
529 |
492 |
$9K |
| 93320 |
|
29 |
24 |
$9K |
| 70498 |
|
174 |
148 |
$9K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
40 |
38 |
$9K |
| 80061 |
Lipid panel |
1,477 |
1,396 |
$9K |
| 96367 |
|
1,512 |
820 |
$9K |
| 76801 |
|
128 |
109 |
$8K |
| J3490 |
Unclassified drugs |
3,533 |
1,711 |
$8K |
| 36415 |
Collection of venous blood by venipuncture |
14,445 |
10,311 |
$8K |
| 84443 |
Thyroid stimulating hormone (TSH) |
5,383 |
4,680 |
$7K |
| 97161 |
|
196 |
173 |
$7K |
| 80047 |
|
1,374 |
1,190 |
$7K |
| 85027 |
|
8,891 |
7,170 |
$6K |
| 76641 |
|
56 |
54 |
$5K |
| 71045 |
Radiologic examination, chest; single view |
2,350 |
2,024 |
$5K |
| 0296T |
|
367 |
311 |
$5K |
| A0425 |
Ground mileage, per statute mile |
273 |
228 |
$5K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
5,968 |
5,149 |
$4K |
| 80320 |
|
2,926 |
2,441 |
$4K |
| 0002A |
|
110 |
110 |
$4K |
| 82962 |
|
6,752 |
3,130 |
$3K |
| 81001 |
|
18,705 |
15,554 |
$3K |
| 0001A |
|
126 |
124 |
$3K |
| 93242 |
|
35 |
30 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
5,789 |
4,122 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,628 |
1,498 |
$3K |
| 72100 |
|
552 |
495 |
$3K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
141 |
134 |
$3K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
38 |
36 |
$2K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
559 |
491 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
763 |
677 |
$2K |
| 99070 |
|
521 |
397 |
$2K |
| 83605 |
|
3,056 |
2,403 |
$2K |
| 85610 |
|
3,888 |
3,121 |
$2K |
| 93970 |
|
15 |
14 |
$2K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
117 |
96 |
$2K |
| 93296 |
|
93 |
81 |
$2K |
| 73030 |
|
592 |
516 |
$2K |
| 76770 |
|
12 |
12 |
$2K |
| 77066 |
Tomosynthesis, mammo |
50 |
45 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,509 |
1,308 |
$2K |
| 86900 |
|
1,166 |
1,032 |
$2K |
| 83690 |
|
7,373 |
6,151 |
$2K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
10,815 |
8,946 |
$2K |
| 86850 |
|
684 |
605 |
$2K |
| 83735 |
|
3,985 |
2,833 |
$1K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
10,257 |
6,644 |
$1K |
| 73610 |
|
581 |
512 |
$1K |
| 87081 |
|
3,048 |
2,734 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
7,870 |
5,935 |
$1K |
| 97116 |
|
19 |
12 |
$1K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,638 |
3,899 |
$1K |
| 73630 |
|
542 |
458 |
$1K |
| 90686 |
|
58 |
51 |
$1K |
| 73564 |
|
502 |
409 |
$920.91 |
| 86901 |
|
1,165 |
1,031 |
$886.35 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
87 |
82 |
$854.51 |
| 84702 |
|
1,187 |
1,018 |
$850.99 |
| A0427 |
Ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) |
15 |
13 |
$818.48 |
| 82803 |
|
1,914 |
1,527 |
$788.86 |
| 86140 |
|
672 |
582 |
$749.39 |
| 73130 |
|
364 |
320 |
$748.50 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
9,265 |
6,965 |
$737.41 |
| 84145 |
|
58 |
55 |
$683.02 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
6,563 |
5,487 |
$681.95 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,891 |
2,441 |
$680.67 |
| 82607 |
|
79 |
75 |
$665.44 |
| 10060 |
|
18 |
13 |
$655.36 |
| 85007 |
|
1,235 |
892 |
$639.88 |
| 82565 |
|
405 |
356 |
$609.71 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,374 |
3,919 |
$596.31 |
| A0429 |
Ambulance service, basic life support, emergency transport (bls-emergency) |
15 |
13 |
$546.70 |
| 93976 |
|
131 |
118 |
$485.54 |
| 85014 |
|
1,385 |
1,167 |
$458.10 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
216 |
173 |
$451.49 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
4,242 |
2,938 |
$449.62 |
| 72070 |
|
14 |
14 |
$444.79 |
| G0008 |
Administration of influenza virus vaccine |
49 |
42 |
$437.42 |
| 87186 |
|
1,589 |
1,351 |
$426.75 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
3,663 |
2,662 |
$424.23 |
| 94664 |
|
324 |
248 |
$423.48 |
| 87077 |
|
590 |
486 |
$411.39 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
3,505 |
2,787 |
$369.14 |
| 87210 |
|
1,186 |
1,033 |
$364.48 |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
42 |
36 |
$329.76 |
| 84439 |
|
181 |
158 |
$324.33 |
| 83615 |
|
2,108 |
1,361 |
$319.78 |
| 85730 |
|
762 |
665 |
$289.17 |
| 81025 |
|
1,545 |
1,408 |
$287.37 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,464 |
1,876 |
$263.72 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
1,380 |
1,129 |
$250.57 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
2,108 |
1,409 |
$207.89 |
| 85651 |
|
445 |
401 |
$193.89 |
| J2060 |
Injection, lorazepam, 2 mg |
1,231 |
771 |
$192.98 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
1,561 |
1,268 |
$189.63 |
| 87807 |
|
677 |
588 |
$176.37 |
| 74022 |
|
75 |
64 |
$171.48 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,630 |
1,267 |
$159.39 |
| 87147 |
|
733 |
642 |
$158.64 |
| 82550 |
|
404 |
337 |
$148.92 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
998 |
657 |
$142.97 |
| 81015 |
|
159 |
148 |
$136.18 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
920 |
699 |
$135.86 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,799 |
2,161 |
$133.52 |
| J1815 |
Injection, insulin, per 5 units |
924 |
376 |
$133.09 |
| 87088 |
|
562 |
497 |
$112.12 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,100 |
952 |
$110.78 |
| 73110 |
|
85 |
71 |
$108.02 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
938 |
720 |
$99.43 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
43 |
42 |
$97.87 |
| 84703 |
|
108 |
101 |
$96.63 |
| S0028 |
Injection, famotidine, 20 mg |
104 |
62 |
$91.48 |
| 73590 |
|
34 |
24 |
$89.86 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
736 |
598 |
$68.59 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
490 |
290 |
$62.84 |
| 82947 |
|
77 |
73 |
$59.01 |
| J1644 |
Injection, heparin sodium, per 1000 units |
442 |
178 |
$57.97 |
| 73502 |
|
47 |
38 |
$57.88 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
459 |
363 |
$55.50 |
| 81003 |
|
140 |
126 |
$54.71 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
418 |
325 |
$54.10 |
| 36600 |
|
14 |
12 |
$52.16 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
356 |
315 |
$49.62 |
| J7050 |
Infusion, normal saline solution, 250 cc |
431 |
253 |
$48.87 |
| 86803 |
|
27 |
27 |
$36.33 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
290 |
230 |
$33.37 |
| 84100 |
|
188 |
152 |
$33.06 |
| 84132 |
|
170 |
122 |
$26.59 |
| 80143 |
|
108 |
82 |
$26.58 |
| 87340 |
|
25 |
25 |
$26.09 |
| 86592 |
|
44 |
42 |
$26.09 |
| J3480 |
Injection, potassium chloride, per 2 meq |
129 |
70 |
$23.88 |
| J1790 |
Injection, droperidol, up to 5 mg |
164 |
143 |
$22.72 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
346 |
162 |
$21.65 |
| 87184 |
|
104 |
93 |
$21.46 |
| S0164 |
Injection, pantoprazole sodium, 40 mg |
90 |
54 |
$16.69 |
| 85652 |
|
16 |
15 |
$15.68 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
94 |
77 |
$14.26 |
| 80179 |
|
108 |
82 |
$13.30 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
65 |
55 |
$11.86 |
| 82570 |
|
14 |
12 |
$10.84 |
| 87205 |
|
120 |
93 |
$8.71 |
| 87070 |
|
83 |
68 |
$8.70 |
| J1630 |
Injection, haloperidol, up to 5 mg |
46 |
30 |
$6.25 |
| C9113 |
Injection, pantoprazole sodium, per vial |
52 |
34 |
$5.29 |
| 96376 |
|
2,849 |
1,906 |
$1.66 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
2,328 |
983 |
$0.00 |
| Q0144 |
Azithromycin dihydrate, oral, capsules/powder, 1 gram |
18 |
12 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
18 |
13 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
231 |
205 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
46 |
30 |
$0.00 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
28 |
25 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
27 |
24 |
$0.00 |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
13 |
12 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
15 |
12 |
$0.00 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
17 |
12 |
$0.00 |
| 84295 |
|
15 |
14 |
$0.00 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
13 |
12 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
1,340 |
1,111 |
$0.00 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
12 |
12 |
$0.00 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
182 |
163 |
$0.00 |
| 82330 |
|
16 |
15 |
$0.00 |
| 86762 |
|
13 |
13 |
$0.00 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
20 |
12 |
$0.00 |
| G1011 |
Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program |
15 |
13 |
$0.00 |